Ticker Details
Aclaris Therapeutics, Inc. Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology.
IPO Date:	October 7, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$797.48M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.36 | 3.76%
Avg Daily Range (30 D):	$0.16 | 3.27%
Avg Daily Range (90 D):	$0.15 | 3.59%

Institutional Daily Volume
Avg Daily Volume:	.77M
Avg Daily Volume (30 D):	1.31M
Avg Daily Volume (90 D):	1.57M

Trade Size
Avg Trade Size (Sh.):	159
Avg Trade Size (Sh.) (30 D):	92
Avg Trade Size (Sh.) (90 D):	135

Institutional Trades
Total Institutional Trades:	1,251
Avg Institutional Trade:	$1.61M
Avg Institutional Trade (30 D):	$1.89M
Avg Institutional Trade (90 D):	$2.24M
Avg Institutional Trade Volume:	.17M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.52M
Avg Closing Trade (30 D):	$2.44M
Avg Closing Trade (90 D):	$1.73M
Avg Closing Volume:	163.09K

News

Mar 20, 2026 @ 3:00 PM Aclaris Therapeutics Announces Poster on Results f... Source: Aclaris Therapeutics, Inc.

Feb 24, 2026 @ 12:00 PM Aclaris Therapeutics Initiates Phase 1b Proof-of-C... Source: Na

Nov 25, 2025 @ 1:00 PM Aclaris Therapeutics to Participate in the Piper S... Source: Will Roberts

Sep 9, 2025 @ 11:00 AM Aclaris Therapeutics Announces Late-Breaking Abstr... Source: Aclaris Therapeutics

Aug 27, 2025 @ 12:00 PM Aclaris Therapeutics to Participate in Two Septemb... Source: Will Roberts

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.56	$-.15	$-.16
Diluted EPS	$-.56	$-.15	$-.16
Revenue	$8.37M	$2M	$1.3M
Gross Profit	$6.39M	$1.6M	$.76M
Net Income / Loss	$-69.66M	$-19.82M	$-19.8M
Operating Income / Loss	$-80.48M	$-22.19M	$-22.73M
Cost of Revenue	$1.98M	$.4M	$.53M
Net Cash Flow	$-1.7M	$8.7M	$-5.3M
PE Ratio